To prioritize druggable genes and reduce the number of candidates to a manageable number, we used the following criteria: (a) the genes are, or have the potential to be, direct MYC targets; (b) the genes have prognostic value in neuroblastoma; and (c) inhibitors are readily available. This evidence concerns the gene MYC and neuroblastoma.